The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Case Report

Aliskiren-Induced QT Interval Prolongation

Authors: Gregory J. Peitz PharmD, Mark A. Malesker PharmD, S George Sojka MD

Abstract

Abstract:Aliskiren gained FDA approval for the treatment of hypertension in 2007. It is the first approved pharmaceutical to manage hypertension by direct renin inhibition. With the introduction of novel drugs and mechanisms of action comes the challenge of monitoring for new unreported adverse events. The side effect profile for aliskiren has not yet been fully described. We describe the first apparent report of aliskiren-induced QT prolongation resulting in torsades de pointes.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

References1. Package Insert. Tekturna® (Aliskiren). East Hanover, NJ, Novartis Pharmaceuticals Corporation, 2007.&NA;Package Insert. Tekturna® (Aliskiren).East Hanover, NJNovartis Pharmaceuticals Corporation20072. Ayalasomayajula S, Yeh CM, Vaidyanathan S, et al. Effects of aliskiren, a direct renin inhibitor, on cardiac repolarization and conduction in healthy subjects. J Clin Pharmacol 2008;48:799–811.AyalasomayajulaS]]YehCM]]VaidyanathanS&etal;Effects of aliskiren, a direct renin inhibitor, on cardiac repolarization and conduction in healthy subjects.J Clin Pharmacol200848799-8113. D’Aloia A, Faggiano P, Brentana A, et al. Sustained torsades de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease. Int J Cardiol 2005;105:337–339.D’AloiaA]]FaggianoP]]BrentanaA&etal;Sustained torsades de pointes occurring early during oral sotalol therapy for atrial fibrillation recurrence prophylaxis in a patient without heart disease.Int J Cardiol2005105337-3394. Link MS, Foote CB, Sloan SB, et al. Torsade de pointes and prolonged qt interval from surreptitious use of sotalol: use of drug levels in diagnosis. Chest 1997;112:556–557.LinkMS]]FooteCB]]SloanSB&etal;Torsade de pointes and prolonged qt interval from surreptitious use of sotalol: use of drug levels in diagnosis.Chest1997112556-5575. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.NaranjoCA]]BustoU]]SellersEM&etal;A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther198130239-245